Keyvan Rezai
Overview
Explore the profile of Keyvan Rezai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
1111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reinhold W, Marangoni E, Elloumi F, Montagne R, Varma S, Wang Y, et al.
Cancer Res Commun
. 2025 Feb;
5(2):375-388.
PMID: 39932272
Acetalax and bisacodyl represent a prospective novel drug mechanism-of-action type, affect mitochondrial function and affect tumor growth in vivo. Their activity may be predicted by TRPM4 but with more accuracy...
2.
Spriano F, Sartori G, Sgrignani J, Barnabei L, Arribas A, Guala M, et al.
Haematologica
. 2024 Jun;
109(11):3602-3614.
PMID: 38899342
Hematologic cancers are among the most common cancers in adults and children. Despite significant improvements in therapies, many patients still succumb to the disease. Therefore, novel therapies are needed. The...
3.
Acramel A, Fouque J, Blondeel-Gomes S, Huguet S, Rezai K, Madar O, et al.
Ann Work Expo Health
. 2022 May;
66(9):1215-1223.
PMID: 35596678
Objectives: The risk of chronic exposure to antineoplastic agents in hospitals, mainly by skin contact with contaminated surfaces, is well established. The aim of this study was to assess indirectly...
4.
Vicier C, Sfumato P, Isambert N, Dalenc F, Robert M, Levy C, et al.
Eur J Cancer
. 2021 Nov;
159:205-214.
PMID: 34781168
Background: Hormone-resistant HER2-negative or triple-negative advanced breast cancers (ABC) are routinely treated with paclitaxel chemotherapy. LY2780301 is a dual inhibitor of p70 ribosomal protein S6 kinase and AKT. The TAKTIC...
5.
Campone M, Bachelot T, Treilleux I, Pistilli B, Salleron J, Seegers V, et al.
Eur J Cancer
. 2021 Oct;
158:169-180.
PMID: 34678678
Introduction: Resistance to trastuzumab in breast cancer is an ongoing challenge. Clinical and biological effects of co-targeting HER2 and mammalian target of rapamycin (mTOR) in patients with HER2-positive early operable...
6.
Sestito S, Bacci A, Chiarugi S, Runfola M, Gado F, Margheritis E, et al.
Eur J Med Chem
. 2021 Oct;
226:113895.
PMID: 34624821
We report the synthesis of novel first-in-class 2-oxindole-based derivatives as dual PDK1-AurA kinase inhibitors as a novel strategy to treat Ewing sarcoma. The most potent compound 12 is suitable for...
7.
Fouque J, Rusu T, Huguet S, Branquinho E, Blondeel-Gomes S, Rezai K, et al.
J Labelled Comp Radiopharm
. 2021 Aug;
64(11):440-446.
PMID: 34355420
Radiolabelling with short half-lives radionuclides (e.g., fluorine-18 and carbon-11) must be as efficient and as fast as possible. Nucleophilic radiofluorinations and radiomethylations are conducted in polar aprotic solvents, such as...
8.
Bautista F, Paoletti X, Rubino J, Brard C, Rezai K, Nebchi S, et al.
J Clin Oncol
. 2021 Aug;
39(32):3546-3560.
PMID: 34347542
Purpose: AcSé-ESMART is a proof-of-concept, phase I or II, platform trial, designed to explore targeted agents in a molecularly enriched cancer population. Arms A and B aimed to define the...
9.
Marret G, Isambert N, Rezai K, Gal J, Saada-Bouzid E, Rolland F, et al.
Invest New Drugs
. 2021 Jul;
39(6):1641-1648.
PMID: 34322775
Background The phosphatidylinositol-3 kinase pathway is often altered in head and neck squamous cell carcinoma (HNSCC), and is involved in the resistance to EGFR inhibitors. Objective We investigated the dose-limiting...
10.
Schmitt C, Fouque J, Huguet S, Branquinho E, Blondeel S, Rezai K, et al.
Appl Radiat Isot
. 2021 Jul;
176:109874.
PMID: 34311218
The radiochemical purity (RCP) determination of radiopharmaceuticals is routinely done with radio-thin layer chromatography (r-TLC). These methods are usually transposed and adjusted from the summary product characteristics without any analytical...